{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:32:42Z","timestamp":1789421562446,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1I1A304950813"],"award-info":[{"award-number":["NRF-2021R1I1A304950813"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003562","name":"Ministry of Environment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002613","name":"Ulsan National Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002568","name":"University of Ulsan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118772","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T13:03:14Z","timestamp":1763470994000},"page":"118772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["TTP enhances the sensitivity of KRASG12C-mutated lung cancer cells to KRASG12C inhibitors by downregulating SLC7A11 and promoting ferroptosis"],"prefix":"10.1016","volume":"193","author":[{"given":"Ki Ra","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9548-0921","authenticated-orcid":false,"given":"Minh-Xuan","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-0898","authenticated-orcid":false,"given":"Ok Joo","family":"Sul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiHeung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Sung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haebin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Won","family":"Ra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk Nam","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wha Ja","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3355-6908","authenticated-orcid":false,"given":"Jeong Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4945","key":"10.1016\/j.biopha.2025.118772_bib1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1126\/science.2406906","article-title":"Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins","volume":"247","author":"Milburn","year":"1990","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.biopha.2025.118772_bib2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","article-title":"A model for RAS mutation patterns in cancers: finding the sweet spot","volume":"18","author":"Li","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"25","key":"10.1016\/j.biopha.2025.118772_bib3","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118772_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"7781","key":"10.1016\/j.biopha.2025.118772_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2025.118772_bib6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"issue":"6273","key":"10.1016\/j.biopha.2025.118772_bib7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.biopha.2025.118772_bib8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7784","key":"10.1016\/j.biopha.2025.118772_bib9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","article-title":"The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis","volume":"575","author":"Bersuker","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2025.118772_bib10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118772_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.trecan.2021.01.009","article-title":"Group behavior and emergence of cancer drug resistance","volume":"7","author":"Bhattacharya","year":"2021","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118772_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing cancer drug resistance in the era of personalized medicine","volume":"2","author":"Garraway","year":"2012","journal-title":"Cancer Discov."},{"issue":"7782","key":"10.1016\/j.biopha.2025.118772_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2025.118772_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2025.118772_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41568-019-0149-1","article-title":"Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion","volume":"19","author":"Friedmann Angeli","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118772_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4143\/crt.2016.572","article-title":"Ferroptosis: a novel anti-tumor action for cisplatin","volume":"50","author":"Guo","year":"2018","journal-title":"Cancer Res. Treat."},{"issue":"7545","key":"10.1016\/j.biopha.2025.118772_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"520","author":"Jiang","year":"2015","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biopha.2025.118772_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","article-title":"Targeting ferroptosis as a vulnerability in cancer","volume":"22","author":"Lei","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"7860","key":"10.1016\/j.biopha.2025.118772_bib19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2025.118772_bib20","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41589-020-0613-y","article-title":"Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers","volume":"16","author":"Soula","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118772_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1535-6108(03)00050-3","article-title":"Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells","volume":"3","author":"Dolma","year":"2003","journal-title":"Cancer Cell"},{"issue":"7146","key":"10.1016\/j.biopha.2025.118772_bib22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature05859","article-title":"RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels","volume":"447","author":"Yagoda","year":"2007","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biopha.2025.118772_bib23","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.7150\/thno.44705","article-title":"Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.biopha.2025.118772_bib24","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-019-2192-y","article-title":"The impact of oncogenic RAS on redox balance and implications for cancer development","volume":"10","author":"Lim","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.biopha.2025.118772_bib25","first-page":"730","article-title":"HMGB1 regulates erastin-induced ferroptosis via RAS-JNK\/p38 signaling in HL-60\/NRAS(Q61L) cells","volume":"9","author":"Ye","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"19","key":"10.1016\/j.biopha.2025.118772_bib26","doi-asserted-by":"crossref","first-page":"9433","DOI":"10.1073\/pnas.1821323116","article-title":"Cystine\/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance","volume":"116","author":"Lim","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118772_bib27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41418-022-01096-8","article-title":"Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation","volume":"30","author":"M\u00fcller","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2025.118772_bib28","article-title":"Oncogenic RAS signaling suppresses ferroptosis via transcriptional upregulation of GCH1","volume":"2024","author":"Lim","year":"2024","journal-title":"bioRxiv"},{"issue":"6-7","key":"10.1016\/j.biopha.2025.118772_bib29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbagrm.2013.02.003","article-title":"Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action","volume":"1829","author":"Brooks","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"5379","key":"10.1016\/j.biopha.2025.118772_bib30","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.281.5379.1001","article-title":"Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin","volume":"281","author":"Carballo","year":"1998","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.biopha.2025.118772_bib31","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1093\/nar\/gkr1302","article-title":"Ectopic over-expression of tristetraprolin in human cancer cells promotes biogenesis of let-7 by down-regulation of Lin28","volume":"40","author":"Kim","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/j.biopha.2025.118772_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113384","article-title":"Roles of tristetraprolin in tumorigenesis","volume":"19","author":"Park","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118772_bib33","article-title":"Tristetraprolin, a potential safeguard against carcinoma: role in the tumor microenvironment","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118772_bib34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41419-024-06436-9","article-title":"Hedgehog signalling is involved in acquired resistance to KRAS(G12C) inhibitors in lung cancer cells","volume":"15","author":"Lee","year":"2024","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.biopha.2025.118772_bib35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/76211","article-title":"The 3\u2032 untranslated region of messenger RNA: a molecular 'hotspot' for pathology?","volume":"6","author":"Conne","year":"2000","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.biopha.2025.118772_bib36","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1074\/jbc.M310486200","article-title":"MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding","volume":"279","author":"Chrestensen","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.biopha.2025.118772_bib37","doi-asserted-by":"crossref","first-page":"18029","DOI":"10.1074\/jbc.M110465200","article-title":"Cytoplasmic localization of tristetraprolin involves 14-3-3-dependent and -independent mechanisms","volume":"277","author":"Johnson","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2025.118772_bib38","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/sj.emboj.7600163","article-title":"MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay","volume":"23","author":"Stoecklin","year":"2004","journal-title":"EMBO J."},{"issue":"6220","key":"10.1016\/j.biopha.2025.118772_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2025.118772_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12865-019-0292-1","article-title":"Tristetraprolin specifically regulates the expression and alternative splicing of immune response genes in HeLa cells","volume":"20","author":"Tu","year":"2019","journal-title":"BMC Immunol."},{"key":"10.1016\/j.biopha.2025.118772_bib41","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1128\/MCB.01068-15","article-title":"Effects of combined tristetraprolin\/tumor necrosis factor receptor deficiency on the splenic transcriptome","author":"Patial","year":"2016","journal-title":"Mol. Cell. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118772_bib42","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41556-019-0305-6","article-title":"ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway","volume":"21","author":"Chu","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"7664","key":"10.1016\/j.biopha.2025.118772_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2025.118772_bib44","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1172\/JCI124049","article-title":"Suppression of the SLC7A11\/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma","volume":"130","author":"Hu","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"12","key":"10.1016\/j.biopha.2025.118772_bib45","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","article-title":"Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11","volume":"9","author":"Lang","year":"2019","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.biopha.2025.118772_bib46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41422-019-0263-3","article-title":"The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression","volume":"30","author":"Lei","year":"2020","journal-title":"Cell Res"},{"issue":"7755","key":"10.1016\/j.biopha.2025.118772_bib47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118772_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2025.101228","article-title":"ZFP36 promotes ferroptosis and mitochondrial dysfunction and inhibits malignant progression in osteosarcoma by regulating the E2F1\/ATF4 axis","author":"Qin","year":"2025","journal-title":"J. Pharm. Anal."},{"issue":"8","key":"10.1016\/j.biopha.2025.118772_bib49","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1080\/15548627.2019.1687985","article-title":"RNA-binding protein ZFP36\/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells","volume":"16","author":"Zhang","year":"2020","journal-title":"Autophagy"},{"issue":"12","key":"10.1016\/j.biopha.2025.118772_bib50","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1158\/0008-5472.CAN-08-4238","article-title":"The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis","volume":"69","author":"Brennan","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.biopha.2025.118772_bib51","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.abb.2007.04.011","article-title":"Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines","volume":"462","author":"Carrick","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"issue":"11","key":"10.1016\/j.biopha.2025.118772_bib52","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1093\/nar\/gkt222","article-title":"Tumor suppressor p53 plays a key role in induction of both tristetraprolin and let-7 in human cancer cells","volume":"41","author":"Lee","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118772_bib53","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cell.2012.06.033","article-title":"Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state","volume":"150","author":"Rounbehler","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2025.118772_bib54","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35106009","article-title":"Assessing TP53 status in human tumours to evaluate clinical outcome","volume":"1","author":"Soussi","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118772_bib55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.ge.20.120186.002045","article-title":"The myc oncogene: its role in transformation and differentiation","volume":"20","author":"Cole","year":"1986","journal-title":"Annu. Rev. Genet"},{"issue":"23","key":"10.1016\/j.biopha.2025.118772_bib56","doi-asserted-by":"crossref","first-page":"17329","DOI":"10.1074\/jbc.M109.094235","article-title":"Stability of the LATS2 tumor suppressor gene is regulated by tristetraprolin","volume":"285","author":"Lee","year":"2010","journal-title":"J. Biol. Chem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:52:17Z","timestamp":1777013537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":56,"alternative-id":["S0753332225009667"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118772","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TTP enhances the sensitivity of KRASG12C-mutated lung cancer cells to KRASG12C inhibitors by downregulating SLC7A11 and promoting ferroptosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118772"}}